Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 117 points (-0.7%) at 16,295 as of Monday, April 7, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 843 issues advancing vs. 2,136 declining with 146 unchanged. The Drugs industry currently sits down 1.4% versus the S&P 500, which is down 0.8%. On the negative front, top decliners within the industry include Valeant Pharmaceuticals International ( VRX), down 3.5%, Actavis ( ACT), down 2.4%, Allergan ( AGN), down 2.2%, Forest Laboratories ( FRX), down 1.7% and AstraZeneca ( AZN), down 0.8%. Top gainers within the industry include Questcor Pharmaceuticals ( QCOR), up 15.4%, Biogen Idec ( BIIB), up 1.5% and Eli Lilly and Company ( LLY), up 0.6%. TheStreet would like to highlight 3 stocks pushing the industry lower today: 3. Amgen ( AMGN) is one of the companies pushing the Drugs industry lower today. As of noon trading, Amgen is down $0.64 (-0.5%) to $118.47 on average volume. Thus far, 2.4 million shares of Amgen exchanged hands as compared to its average daily volume of 3.5 million shares. The stock has ranged in price between $116.56-$119.74 after having opened the day at $118.19 as compared to the previous trading day's close of $119.11. Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine worldwide. Amgen has a market cap of $93.7 billion and is part of the health care sector. Shares are up 4.4% year-to-date as of the close of trading on Friday. Currently there are 7 analysts that rate Amgen a buy, no analysts rate it a sell, and 11 rate it a hold. TheStreet Ratings rates Amgen as a buy. The company's strengths can be seen in multiple areas, such as its increase in stock price during the past year, impressive record of earnings per share growth, compelling growth in net income, revenue growth and notable return on equity. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Amgen Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.